TRXB Stock Chart & Stats
14.03
0.03(0.21%)
―
--
Day’s Range― - ―
52-Week Range13.50 - 15.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$385.06M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,445,683
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TRex Bio, Inc. News
TRXB FAQ
What was TRex Bio, Inc.’s price range in the past 12 months?
TRex Bio, Inc. lowest stock price was 13.50 and its highest was 15.50 in the past 12 months.
What is TRex Bio, Inc.’s market cap?
TRex Bio, Inc.’s market cap is $385.06M.
When is TRex Bio, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TRex Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is TRex Bio, Inc. overvalued?
According to Wall Street analysts TRex Bio, Inc.’s price is currently Undervalued.
Does TRex Bio, Inc. pay dividends?
TRex Bio, Inc. does not currently pay dividends.
What is TRex Bio, Inc.’s EPS estimate?
TRex Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TRex Bio, Inc. have?
TRex Bio, Inc. has 27,445,683 shares outstanding.
What happened to TRex Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TRex Bio, Inc.?
Currently, no hedge funds are holding shares in TRXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TRex Bio, Inc. Stock Smart Score
Company Description
TRex Bio, Inc.
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
Corcept Therapeutics
―
Kiniksa Pharmaceuticals
―
Citius Oncology
―
Clinuvel Pharmaceuticals Limited Sponsored ADR
―
Electra Therapeutics Inc.
―